From the optimism file: 71% of healthcare execs expect revenues to increase this year

Healthcare executives maintain a positive outlook for 2016, with 71 percent expecting their revenues to increase this year and 55 percent expecting to seek financing in the next 12 months, according to a survey released by financial firm CIT Group.

The findings were based off a Harris poll conducted among 164 healthcare executives. 

“The majority of the surveyed healthcare executives remain optimistic, expecting similar growth to last year in revenue, prices, volume and capital spending,” said William Douglass, Group Head and Managing Director, CIT Healthcare Finance.

“With a promising financial outlook, it is not surprising that nearly half of executives surveyed also believe that capital spending will increase in the coming year,” he added. “Moreover, the need for financing is expected to hold steady or increase.”

Some key statistics from the study include:

  • Demand for financing grows: 55 percent believe that their company is likely to seek financing in the next year.
  • M&A seen as on the rise: 53 percent of healthcare executives imagine that mergers and acquisitions will increase across the industry as 41 percent believe it will remain stable.
  • Industry will rely on technology to move forward: 80 percent executives believe that patients should be using technology to monitor their healthcare needs, and 88 percent cite security as a clear concern that must be addressed.
  • Costs continue to pose a challenge: 91 percent feel that consumers will be unable to afford any higher healthcare costs than the current standard.
  • Some government involvement welcomed by executives: 78 percent of executives believe that the government should maintain at least some role in and authority over the healthcare industry.
  • Alignment with industry standards on outcomes: 72 percent felt that their sector is on track with the rest of the industry on how to best measure outcomes.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.